冠心病心血管事件发生的主要病理基础为冠状动脉内血栓，诱发冠状动脉内血栓形成的关键病理环节是炎症反应和血小板活化。因此，从炎症反应和血小板活化方面探索血栓前状态发生和活血化瘀中药对其干预的分子机理，对预防冠心病心血管事件具有重要意义。本课题在前期工作的基础上，基于炎症-血小板-血栓网络，通过甲襞微循环和血小板聚集率筛查冠心病稳定性心绞痛血栓前状态患者，利用芯片技术筛选与炎症-血小板-血栓形成相关的目标miRNA；通过apoE基因敲除小鼠动脉粥样硬化模型、大鼠冠脉微血栓模型和内皮细胞损伤模型，研究目标miRNA对炎症-血小板-血栓网络的调控作用。在此基础上，观察活血化瘀中药稳定动脉粥样硬化斑块、抑制血栓形成的效应，探索其调控炎症-血小板-血栓形成相关miRNA表达的分子机理，以为活血化瘀中药预防冠心病血栓前状态血栓形成提供实验依据和分子靶向。

The main pathology of coronary heart disease and cardiovascular events is coronary artery thrombosis, and the key aspect of the formation of coronary artery thrombosis is platelet activation and inflammation. Thus, to explore the molecular mechanism of prethrombotic state and the effect of traditional Chinese medicine through platelet activation and inflammation is of great importance for the prevention of cardiovascular events in coronary heart disease. On the basis of previous work, this issue selects stable angina patients in the prethrombotic state by nailfold microcirculation test and platelet aggregation rate examination, and screens the target miRNAs by means of chip technology based on inflammation - platelets - thrombus network. And then the regulation effect of these target miRNAS will be studied through apoE knockout mice model of atherosclerosis, microthrombosis model in rats and endothelial cell injury model. Based on these, we further explore the effect of Huoxue huayu medicine on platelet activation, atherosclerotic plaques to identify the molecular mechanism of miRNA on prethrombotic state and provide experimental evidence and molecular targeting for the usage of traditional Chinese medine.